Do SGLT2i, GLP-1 RAs Cut Pneumonia, Sepsis Risk?
-
By
December 9, 2024
-
3 min
A large-scale study assessed the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on pneumonia and severe sepsis risks in adults with type 2 diabetes. The study found that treatment with GLP-1 RAs was associated with a 40% reduction in pneumonia risk among patients with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors (DPP-4i). Similarly, SGLT2i use was associated with a 25% reduced risk of pneumonia and severe sepsis compared to DPP-4i. The findings suggest potential benefits from these therapies in reducing pneumonia and severe sepsis risks, possibly through weight loss-mediated reduction in chronic inflammation and cardiorenal protection for GLP-1 RAs, and improved oxygen delivery to lung tissue for SGLT2i.
1. GLP-1 RAs associated with 40% reduced pneumonia risk in type 2 diabetes patients. 2. SGLT2i linked to a 25% reduced risk of pneumonia and severe sepsis. 3. Potential benefits include weight loss-mediated inflammation reduction and improved oxygen delivery to lung tissue. 4. Study limitations include potential residual confounding and challenges in tracking drug switching. 5. The need for randomized controlled trials to explore mechanisms behind associations is emphasized.
Listen Tab content
